3 Houston innovators to know this week

who's who

This week's roundup of Houston innovators includes Chris George of Octopus EV, James Allison of MD Anderson, and Paul Wotton of RBL LLC. Photos courtesy

Editor's note: Every week, I introduce you to a handful of Houston innovators to know recently making headlines with news of innovative technology, investment activity, and more. This week's batch includes a biotech leader, a Nobel laureate, and EV innovator.

Chris George, United States co-lead at Octopus Electric Vehicles

Chris George, United States co-lead at Octopus Electric Vehicles, joins the Houston Innovators Podcast. Photo courtesy of Octopus

Switching from a gas-powered car to an electric one can be a big change, but a Houston-based company has made things a lot easier for its customers.

Octopus Electric Vehicles US, a spinout of United Kingdom-based retail energy provider Octopus Energy, matches its users with their perfect EV lease and sets them up with smart electricity technology for at-home charging.

"We do a couple of really unique things that are not only first of its kind but really innovative," Octopus EV's US Co-Lead Chris George says on the Houston Innovators Podcast, pointing out specifically Octopus Energy's Intelligent Octopus, a smart feature for customers that automates energy usage to lower cost.

"We launched an Intelligent Octopus for EVs service. Instead of operating in a very narrow window — overnight — it operates dynamically," he continues. Read more.

James P. Allison, director of the James P. Allison Institute

MD Anderson's lab led by Nobel laureate James Allison has secured a $5 million donation. Photo courtesy of MD Anderson Cancer Center

The James P. Allison Institute at The University of Texas MD Anderson Cancer Center scored a $5 million gift at its second annual symposium.

On behalf of Mayor John Whitmire, Oct. 10, 2024 was named “James P. Allison Institute Day,” and it was also the day that the TMC3 Collaborative Building in the Texas Medical Center’s Helix Park greeted 900 attendees for the scientific symposium, entitled “Immunotherapy in Space and Time: The Tumor Microenvironment.”

“Spatial biology is a rapidly expanding field that offers tremendous new insights into immunobiology that were not possible just a few short years ago. Understanding how immune cells interact with their neighbors and with tumor cells in space and time will enable us to bring forward new strategies to improve immunotherapy outcomes,” says James P. Allison. “We are proud to host this annual symposium to advance the field, and we are extremely grateful for the support of the Wintermann Foundation to make new breakthroughs possible.” Read more.

Paul Wotton, managing partner of RBL LLC

Established to rapidly build companies based on Rice University's portfolio of over 100 patents, RBL LLC is Rice University's new biotech venture creation studio based in Texas Medical Center Helix Park. RBL comes on the heels of establishing the Rice Biotech Launch Pad, a biotech innovation accelerator that opened last year.

Paul Wotton, executive director of the Rice Biotech Launch Pad, co-founded RBL with his colleagues Omid Veiseh, Rice professor of bioengineering and faculty director of the Rice Biotech Launch Pad; Jacob Robinson, Rice professor of electrical and computer engineering; and Dr. Rima Chakrabarti, a physician scientist and venture capital investor with KdT Ventures.

“This is a pivotal moment for Houston and beyond,” Wotton, who serves as RBL’s managing partner, says in a news release from Rice. “Houston has rapidly emerged as a global life sciences powerhouse, blending cutting-edge research with early clinical applications at Rice and the city’s world-renowned hospital systems." Continue reading.

From advice to observations, these five quotes overheard at SXSW proves Houston had some great spokespeople at the 2019 SXSW Interactive festival. Photos courtesy

Overheard: 5 powerful quotes from Houstonians speaking at SXSW

Eavesdropping in Austin

Houston had no shortage of representatives at the 2019 SXSW Interactive festival, which took place March 8 to 12 in Austin. Several sat on panels, lead mixers, or even starred in a movie for the film track of the conference.

I had the pleasure of sitting in on a great deal of these events featuring the best and the brightest of Houston's innovation stars, but I realize most did not. To catch you up and rid you of your fear of missing out, check out these five overheard quotes from the fest.

"I think it's so important to find your focus and know what to say no to, because you can't do it all. Elizabeth [Gore] and I have a monthly 'meeting of no' where we literally check off things off our plate that we need to stop doing because we just don't have enough time. It's probably one of our most valuable hours."

— Carolyn Rodz, co-founded Alice with Elizabeth Gore. Alice co-hosted a series of panels at the Bumble Hive. She was asked, during the investment-focused panel, about focusing on B-to-B vs. B-to-C as a startup. Alice and Bumble just recently announced a partnership.

"We're trying to awaken the sleeping giant — a really huge city with lots of money, trying to infiltrate and activate huge family offices and rally people behind the goal of building a vibrant startup community. We've got a long way to go in terms of attracting VC talent — we're still behind Austin and Dallas."

— Lawson Gow, founder and CEO of The Cannon, at the Austinpreneur podcast recording of "The Texas Startup Manifesto" episode. He was asked about what he's been trying to accomplish at The Cannon. Gow is the son of InnovationMap's parent company's CEO.

"We've got all the basic tools, and we know what the main issues are. There's still a lot to do, but we need to be smart and do fact-based and mechanism-based combinations."

— James Allison, chair of Immunology and executive director of the Immunotherapy Platform at MD Anderson Cancer Center. At his panel, "Making the Fight Against Cancer Even More Personal," he was asked about the current status of immunotherapy research.

“Have very specific questions. I hate the ‘can I pick your brain’ request. If you want advice on something, ask me that specifically. And, show up at everything. … It’s not about what network you have, but how many networks you can get into.”

— Grace Rodriguez, CEO and executive director of Impact Hub Houston. On the "Equitable Growth Ecosystems for Entrepreneurs" panel, she was asked about how an entrepreneur might try to grow their network and mentorship.

"Houston is an incredibly industrial town. We have more Fortune 500 companies here than anywhere other than New York — most of them in the world of the dirty and dangerous. We don't have a lot of scooter companies."

— Gabriella Rowe, CEO of Station Houston. She was asked while on her panel, "Startup Funding: From Apprenticeships to Professions," about bootstrapping as a startup. Read more about this discussion here.

Jim Allison, immunotherapy researcher at MD Anderson and Nobel Prize recipient, is the subject of a new film that premiered at SXSW. Photo courtesy of MD Anderson Cancer Center

Film about Nobel Prize-winning Houston scientist premieres at SXSW

Now showing

For most of his career, James Allison has been a cancer research wildcatter fighting an oftentimes lonely battle for the advancement of immunotherapy. The medical community has historically been skeptical of the science, but nonetheless Allison dedicated his life to developing a better treatment to the disease that has claimed so many lives — including his mother's.

Last year, Allison, the chair of Immunology and executive director of the Immunotherapy Platform at MD Anderson, won the 2018 Nobel Prize in medicine, and Breakthrough, a film about Allison's progression from early researcher to Nobel Prize recipient, premiered on March 9 at the 2019 SXSW Interactive festival.

But despite the Nobel Prize and the new film both validating the science to the public, Allison says there's a lot more work to be done in immunotherapy. Allison, his colleague, Padmanee Sharma, and the filmmaker for Breakthrough, Bill Haney, hosted a discussion at SXSW about the future of immunotherapy.

"It's a time of considerable optimism — and we're just at the beginning," says Allison.

The film focuses on the man behind the science — a 70-year-old, harmonica-playing researcher from small-town Alice, Texas. It's both an ode to Allison's career and a thought-provoking take on all the work left to be done in the industry.

Immunotherapy is the process of targeting one's immune system's T-cells, infection-fighting white blood cells, to attack cancer cells. Sharma, a fellow MD Anderson oncology expert and clinician, says their work has received clinical approvals for treating Melanoma, kidney cancer, lung cancer, and bladder cancer. The scientists are now focused on expanding that treatment to other cancer types and building upon the established platform they've created, while also making sure nothing comes in the way of the facts of the science.

"It really requires that we dedicate ourselves to the basic science, understanding it and educating people about it, so we don't allow the facts and science get muddied by things that are political or nonfactual," Sharma says.

In a lot of ways, this is what Breakthrough has been able to do — communicate the facts on a platform where anyone can understand the science.

"We have a revolution on our hands, and thankfully we have people like Bill who can really tell the story well, because maybe as a scientist and a clinician, we're not always equally talented on telling the story to laypeople," Sharma says.

Moving forward, Allison says he's focused on finding out why the treatment fails in some instances, and he's determined to progress immunotherapy's success rate from the 20 to 40 percent rate he says he sees it at now to 100 percent.

"We've got all the basic tools, and we know what the main issues are," Allison says. "There's still a lot to do, but we need to be smart and do fact-based and mechanism-based combinations."

From pitch competitions to panels, here's how Houstonians will be representing at SXSW. Marie Ketring/via sxsw.org

10 can't-miss events at SXSW featuring Houston speakers

South by the Bayou

Plenty of Houstonians, SXSW badge in hand, will be headed to Austin to network, learn, and share the stage with the rest of the festivals attendees. While InnovationMap has highlighted a few of the faces to be on the lookout for this weekend, here's a roundup of 10 events that have a Houston speaker or participant.

3/8 — Featured Session: Opening Speaker, Brené Brown

SXSW is starting right out of the gate with a Houstonian. Brene Brown, a research professor at the University of Houston, will be the keynote address. Her thoughtful talk will focus on community and one's sense of belonging.

The SXSW keynote address will be at 11 am on Friday, March 8, at the Austin Convention Center. Learn more.

3/8 — Hysteria No More: Data, Doctors and Women’s Health

Gone are the days that medical professionals dismiss women's health concerns as "hysteria," but there's still room for improvement on the matter. Three ob/gyns will talk about new ways women are finding health care solutions outside the doctor's office.

Rashmi Kudesia, physician at CCRM Fertility Houston, is one of the panelists, which occurs on Friday, March 8, at the JW Marriott. Learn more.

3/8 — Equitable Growth Ecosystems for Entrepreneurs panel

The country has an equity problem — especially when it comes to startups and funding. Nationally, venture capital funds are not distributed in a way that represents the populations diversity, so how does the industry right the course?

Grace Rodriguez of Impact Hub Houston is among the panel that will discuss this at 3:30 pm on Friday, March 8, at the Hilton Austin Downtown. Learn more.

3/9 — Austinpreneur: The Texas Startup Manifesto

Texas is among the growing innovation ecosystems in the world, but there's plenty of untapped potential. This Capital Factory panel will focus on taking Texas to the next level.

Lawson Gow, founder and CEO of The Cannon, will be a panelist at the event, which begins at 11 am on Saturday, March 9, at the Hilton Austin Downtown. Learn more.

3/9 — Startup Funding: From Apprenticeships to Professions

Venture capitalism has changed tenfold since its start. Looking back on the history of early stage funding can help predict where it's going — from Silicon Valley to every corner of the world.

Station Houston CEO Gabriella Rowe is on the panel, which will take place at 12:30 pm on Saturday, March 9, at the Hilton Austin Downtown. Learn more.

3/9 — Making the Fight Against Cancer Even More Personal

No one loves discussing cancer, but there's a large group of scientists who have to daily and they develop new technologies and innovations to help discover a cure for the deadly affliction.

James Allison, researcher at the University of Texas MD Anderson Cancer Center and 2018 Nobel Prize recipient, will be on the panel discussing ways to innovate within cancer research. The program starts at 5 pm on Saturday, March 9, at the JW Marriott. Learn more.

3/10 — SXSW Pitch Presented by Cyndx Awards Ceremony

Two Houston startups are competing for an award in the 11th annual SXSW Pitch Event. Fluidity Technologies will be presenting as its drone controller, FT Aviator, in the Hyper-Connected Communities category on Saturday, March 9, at 5 pm, and Zibrio SmartScale, which is in the Health and Wearable category, will present on Sunday, March 10, at 5 pm.

The pitch awards will take place at 6:30 pm on Sunday, March 10, at the Hilton Austin Downtown. Learn more.

3/11 — Tech Diversity Report Card 2019

Is diversity and inclusion basically just a myth in technology? Is it something that's attainable at this point, and what can the industry do to make that happen? A group of panelists discuss based on their experience and observations.

Heidi Hoover, head of office at Houston-based Flanders Investment & Trade, will be a member of the panel, which occurs on Monday, March 11, at 5 pm, at Capital Factory. Learn more.

3/11 — Angel Investor Meetup

Calling all acting and aspiring investors — it's time to rally. Two Texas investors are gathering the troops to discuss trends and opportunities in the state's — and the world's — investment sector.

Samantha Lewis of Houston-based GOOSE Society of Texas will be one of the hosts of the meetup, which takes place on Monday, March 11, at 5 p.m, at the Fairmont Hotel. Learn more.

3/12 — AI & IoT Panel and Emerging Company Showcase

Houston-based Baker Botts and Global Corporate Venturing are setting the stage for emerging tech companies to shine. The event includes a panel, a showcase, and an evening of networking.

James McKell, of Chevron Technology Ventures, is representing Houston on the panel, which begins at 2 pm on Tuesday, March 12, at Hotel Van Zandt. Learn more.

Honorable mentions


Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

SpaceX IPO set to be biggest ever and could make Elon Musk a trillionaire

IPO News

SpaceX says it plans to raise up to $75 billion when it goes public this month, setting the stage for the largest-ever stock market debut and putting Elon Musk on course to becoming the world's first trillionaire.

The company, formally known as Space Exploration Technologies Corp., said Wednesday it will sell 555.6 million shares at $135 a piece in an initial public offering. The estimated proceeds would easily top the $26 billion raised by oil giant Saudi Aramco in 2019. The offering would also give SpaceX a market value of $1.77 trillion. Only six companies in the S&P 500 are currently worth more, with Nvidia tops at $5.2 trillion.

Besides the size of the offering and the expected proceeds, SpaceX's amended prospectus updates details about how much control of the company Musk will have. As SpaceX's CEO, chief technical officer and chairman, Musk's voting power will come primarily through his ownership of 5.22 billion Class B shares, which give the holder 10 votes for every share held. According to the filing, Musk would have 82.4% of the voting power in the company.

Forbes currently values Musk's net worth at $826 billion and his stake in SpaceX at $542 billion. The estimated value of his SpaceX holdings was based on an overall value for the company of $1.25 trillion. Based on those numbers, a $1.77 trillion valuation for SpaceX would boost Musk's net worth by $223 billion, making him a trillionaire. However, much of Musk's worth is in stock that he has yet to cash in.

Even as it makes a bid for a blockbuster market debut, SpaceX is currently losing billions of dollars a year. The filing shows that the company lost $2.6 billion from operations last year on $18.7 billion in revenue, and the losses kept piling up at the start of this year, too.

Fantastical plans

Time will tell how SpaceX fares on the market. Musk's plans for the company are as fantastical as the money he hopes raise in the sale.

Colorful, even frightening in parts, the IPO document strikes a contrast with the typically dry, technical prose in IPO documents, detailing plans to use proceeds from the sale to help put men on the moon again and perhaps even Mars. In one section, it talks of a need to build "a permanent human colony" on the red planet with "at least one million inhabitants" as existential threats loom that could consign man to "the same fate as the dinosaurs."

Musk has almost equally ambitious plans for his other publicly traded company, Tesla. His goal is to transform the maker of electric vehicles into a producer of robotaxis and humanoid robots. Dan Ives of Wedbush Securities wrote in a research note that he expects Tesla and SpaceX to merge next year.

AI plays a key role

Key to the success of both companies — and any merged entity — is artificial intelligence. In its IPO filing, SpaceX says it sees potential revenue from AI of up to $26.5 trillion. But that depends on another lofty Musk ambition — putting data centers in space, which is not technologically possible at the moment.

Transforming his space company into a primarily AI-focused company will be a challenge for Musk, who started xAI in 2023 with 11 other co-founders who have all since left. Some were recruited away by rivals.

Its main AI product, the chatbot Grok, is "less impressive than anything that we see from any other major player in the space, whether that's OpenAI, or Anthropic, or (Google's) Gemini," said IDC analyst Arnal Dayaratna.

Dayaratna said that doesn't mean SpaceX doesn't have potential as a major AI player, thanks in part to its computing partnership with Anthropic and Musk's recent deal that gave SpaceX the rights to buy AI coding tool Cursor for $60 billion later this year. Folding in Cursor's capabilities would give SpaceX access to the coveted business customers now using Anthropic's Claude or OpenAI's ChatGPT.

SpaceX plans to use the net proceeds from the IPO to fund the expansion of infrastructure for its AI and rocket businesses, and to beef up the constellation of satellites that power Starlink Mobile, among other investments.

The company plans to list on the Nasdaq under the symbol "SPCX" and could begin trading as soon as the end of next week.

And SpaceX isn't the only colossal market debut investors are now bracing for. Earlier this week, Anthropic submitted a confidential filing with the U.S. Securities and Exchange Commission to officially start its own IPO clock.

OpenAI has not yet reported filing the initial SEC paperwork, but an IPO from the ChatGPT maker is widely expected.

"This listing represents the first major test for public markets after years of muted IPO activity with SpaceX paving the way for AI giants Anthropic and OpenAI to follow soon after," Ives wrote.

___

Associated Press Technology Writer Matt O'Brien contributed.

New UH survey reveals concerns over AI data center growth in Houston

data findings

A new report out of the University of Houston shows that area residents remain wary of the long-term effects of operating data centers.

The recent survey from the University of Houston’s latest SPACE City Panel, conducted by the Center for Public Policy at the Hobby School of Public Affairs, shows that while 85 percent of Houston-area residents use AI, nearly 63 percent oppose the construction of AI data centers within 1 mile of their homes.

Respondents’ concerns centered around data centers’ high energy demand and the area’s power grid reliability. According to the survey, 32 percent of residents who oppose local data center projects would be more likely to support the centers if they relied on renewable energy over fossil fuels.

“Respondents understand that AI can bring economic and educational benefits, but they are also concerned about the physical infrastructure needed to fuel AI, especially data centers,” Soran Mohtadi, post-doctoral fellow at the Hobby School and a researcher on the report, said in a news release. “This physical infrastructure demands more electricity and water, leading to environmental impacts.”

Experts estimate that 6.5 gigawatts of data center capacity will be added to the Texas grid by 2030. And Houston’s data center capacity is predicted to more than double by 2028.

The Electric Reliability Council of Texas also projects electricity demand could reach 218 gigawatts by 2031, which would be more than double the record peak set in August 2023. Data centers are expected to account for 86 gigawatts of that new demand.

Survey respondents also said they are concerned about the state's future water supply, given the large amounts of water that data centers need to stay cool.

In terms of who’s responsible for that issue, 57.6 percent of respondents said they put the onus on Texas lawmakers, while 31.5 percent say tech companies should be responsible.

Additionally, more than 75 percent of respondents believed that data center developers and technology companies—not residents—should bear the cost of infrastructure upgrades to support data centers.

“Every decision legislators make has implications on residents’ everyday lives and local infrastructure now and in the future,” Maria P. Perez Arguelles, lead researcher on the report and research assistant professor at the Hobby School, added in the news release. “This issue is going to become more important in years to come, so this is just the beginning.”

Read the full report here.

Houston-born Cemvita makes breakthrough in sustainable fuel production

clean fuels

Houston-based biotech company Cemvita announced that it recently reached a critical milestone in the development of its FermOil product, which can be used to create Sustainable Aviation Fuel (SAF) and other renewable fuels at industrial scale.

The company shared in a news release that it completed a 75,000-liter industrial fermentation run at Belgium's Bio Base Europe Pilot Plant.

The campaign achieved target technical metrics for the production of FermOil, Cemvita’s renewable natural oil (RNO). FermOil is produced from industrial crude glycerin, an industrial byproduct, as opposed to traditional sugar-based feedstocks used in many bio-oil fermentation processes. It's designed to be a drop-in feedstock for creating SAFs.

Cemvita had previously advanced its FermOil production process through multiple scale-up stages before successfully reaching the 75,000-liter demonstration campaign, according to the company.

“This is not just a fermentation milestone,” Moji Karimi, CEO at Cemvita, said in the release. “It is a blueprint for how existing industrial infrastructure can evolve into circular bioeconomy infrastructure. Every biodiesel plant generating crude glycerin is a potential platform for renewable natural oil production.”

The milestone also supports the deployment of Cemvita’s industrial biomanufacturing platform, FermWorks, which integrates with existing energy and industrial infrastructure to turn waste carbon streams into SAFs and other materials. According to the release, Cemvita plans to move forward with commercial deployment discussions with partners in Brazil, Europe and in the UK. Cemvita already has a partnership with the Brazilian sustainable research institution REMA.

“We are proud to support innovative companies like Cemvita in scaling breakthrough industrial biotechnology solutions,” Hendrik Waegeman, head of business operations at Bio Base Europe Pilot Plant, added in the release. “Successfully operating at the 75,000-liter scale using a feedstock such as crude glycerin highlights both the maturity of the technology and the quality of the scale-up execution achieved by the Cemvita team.”

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

View All Listings